COVID-19 Impact on Global Bio Similars/Subsequent Entry Biologic Market Size, Status and Forecast 2020-2026
This report focuses on the global Bio Similars/Subsequent Entry Biologic status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Bio Similars/Subsequent Entry Biologic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study
The key players covered in this study
- Sun Pharma
- Synthon Pharmaceuticals
- Teva Pharmaceutical Industries
- LG Life Sciences
- Celltrion Biocon
- Hospira
- Merck
- Biogen idec
- Genentech (Roche)
- Pfizer
- Celltrion
- Biocon
- Amgen
- Samsung Biologics
- Mylan
- Dr. Reddy's Laboratories
- Stada Arzneimittel AG
- AbbVie
- Sanofi-Aventis
- Johnson & Johnson
- Novo Nordisk
- Eli Lilly
- Novartis
- 3sbio
- Biotech
- Gelgen
- Innovent
- Dong Bao
- Ganlee
- Monoclonal Antibodies
- Interferon
- Erythropoietin
- Insulin
- Vaccines
- Other
- Tumor
- Diabetes
- Cardiovascular
- Hemophilia
- Other
- North America
- Europe
- China
- Japan
- Southeast Asia
- India
- Central & South America
- To analyze global Bio Similars/Subsequent Entry Biologic status, future forecast, growth opportunity, key market and key players.
- To present the Bio Similars/Subsequent Entry Biologic development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
- To strategically profile the key players and comprehensively analyze their development plan and strategies.
- To define, describe and forecast the market by type, market and key regions.
- History Year: 2015-2019
- Base Year: 2019
- Estimated Year: 2020
- Forecast Year 2020 to 2026
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bio Similars/Subsequent Entry Biologic Revenue
1.4 Market Analysis by Type
1.4.1 Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Monoclonal Antibodies
1.4.3 Interferon
1.4.4 Erythropoietin
1.4.5 Insulin
1.4.6 Vaccines
1.4.7 Other
1.5 Market by Application
1.5.1 Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2020 VS 2026
1.5.2 Tumor
1.5.3 Diabetes
1.5.4 Cardiovascular
1.5.5 Hemophilia
1.5.6 Other
1.6 Coronavirus Disease 2019 (Covid-19): Bio Similars/Subsequent Entry Biologic Industry Impact
1.6.1 How the Covid-19 is Affecting the Bio Similars/Subsequent Entry Biologic Industry
1.6.1.1 Bio Similars/Subsequent Entry Biologic Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Bio Similars/Subsequent Entry Biologic Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Bio Similars/Subsequent Entry Biologic Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Bio Similars/Subsequent Entry Biologic Market Perspective (2015-2026)
2.2 Bio Similars/Subsequent Entry Biologic Growth Trends by Regions
2.2.1 Bio Similars/Subsequent Entry Biologic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bio Similars/Subsequent Entry Biologic Historic Market Share by Regions (2015-2020)
2.2.3 Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bio Similars/Subsequent Entry Biologic Market Growth Strategy
2.3.6 Primary Interviews with Key Bio Similars/Subsequent Entry Biologic Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Market Size
3.1.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Revenue (2015-2020)
3.1.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Players (2015-2020)
3.1.3 Global Bio Similars/Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio
3.2.1 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bio Similars/Subsequent Entry Biologic Revenue in 2019
3.3 Bio Similars/Subsequent Entry Biologic Key Players Head office and Area Served
3.4 Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service
3.5 Date of Enter into Bio Similars/Subsequent Entry Biologic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Bio Similars/Subsequent Entry Biologic Historic Market Size by Type (2015-2020)
4.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Type (2021-2026)
5 BIO SIMILARS/SUBSEQUENT ENTRY BIOLOGIC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
5.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
6.2 Bio Similars/Subsequent Entry Biologic Key Players in North America (2019-2020)
6.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
6.4 North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
7.2 Bio Similars/Subsequent Entry Biologic Key Players in Europe (2019-2020)
7.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
7.4 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
8 CHINA
8.1 China Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
8.2 Bio Similars/Subsequent Entry Biologic Key Players in China (2019-2020)
8.3 China Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
8.4 China Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
9.2 Bio Similars/Subsequent Entry Biologic Key Players in Japan (2019-2020)
9.3 Japan Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
9.4 Japan Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
10.2 Bio Similars/Subsequent Entry Biologic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
10.4 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
11 INDIA
11.1 India Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
11.2 Bio Similars/Subsequent Entry Biologic Key Players in India (2019-2020)
11.3 India Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
11.4 India Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
12.2 Bio Similars/Subsequent Entry Biologic Key Players in Central & South America (2019-2020)
12.3 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
12.4 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Sun Pharma
13.1.1 Sun Pharma Company Details
13.1.2 Sun Pharma Business Overview and Its Total Revenue
13.1.3 Sun Pharma Bio Similars/Subsequent Entry Biologic Introduction
13.1.4 Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020))
13.1.5 Sun Pharma Recent Development
13.2 Synthon Pharmaceuticals
13.2.1 Synthon Pharmaceuticals Company Details
13.2.2 Synthon Pharmaceuticals Business Overview and Its Total Revenue
13.2.3 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Introduction
13.2.4 Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.2.5 Synthon Pharmaceuticals Recent Development
13.3 Teva Pharmaceutical Industries
13.3.1 Teva Pharmaceutical Industries Company Details
13.3.2 Teva Pharmaceutical Industries Business Overview and Its Total Revenue
13.3.3 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Introduction
13.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.3.5 Teva Pharmaceutical Industries Recent Development
13.4 LG Life Sciences
13.4.1 LG Life Sciences Company Details
13.4.2 LG Life Sciences Business Overview and Its Total Revenue
13.4.3 LG Life Sciences Bio Similars/Subsequent Entry Biologic Introduction
13.4.4 LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.4.5 LG Life Sciences Recent Development
13.5 Celltrion Biocon
13.5.1 Celltrion Biocon Company Details
13.5.2 Celltrion Biocon Business Overview and Its Total Revenue
13.5.3 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Introduction
13.5.4 Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.5.5 Celltrion Biocon Recent Development
13.6 Hospira
13.6.1 Hospira Company Details
13.6.2 Hospira Business Overview and Its Total Revenue
13.6.3 Hospira Bio Similars/Subsequent Entry Biologic Introduction
13.6.4 Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.6.5 Hospira Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview and Its Total Revenue
13.7.3 Merck Bio Similars/Subsequent Entry Biologic Introduction
13.7.4 Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Biogen idec
13.8.1 Biogen idec Company Details
13.8.2 Biogen idec Business Overview and Its Total Revenue
13.8.3 Biogen idec Bio Similars/Subsequent Entry Biologic Introduction
13.8.4 Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.8.5 Biogen idec Recent Development
13.9 Genentech (Roche)
13.9.1 Genentech (Roche) Company Details
13.9.2 Genentech (Roche) Business Overview and Its Total Revenue
13.9.3 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Introduction
13.9.4 Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.9.5 Genentech (Roche) Recent Development
13.10 Pfizer
13.10.1 Pfizer Company Details
13.10.2 Pfizer Business Overview and Its Total Revenue
13.10.3 Pfizer Bio Similars/Subsequent Entry Biologic Introduction
13.10.4 Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.10.5 Pfizer Recent Development
13.11 Celltrion
10.11.1 Celltrion Company Details
10.11.2 Celltrion Business Overview and Its Total Revenue
10.11.3 Celltrion Bio Similars/Subsequent Entry Biologic Introduction
10.11.4 Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.11.5 Celltrion Recent Development
13.12 Biocon
10.12.1 Biocon Company Details
10.12.2 Biocon Business Overview and Its Total Revenue
10.12.3 Biocon Bio Similars/Subsequent Entry Biologic Introduction
10.12.4 Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.12.5 Biocon Recent Development
13.13 Amgen
10.13.1 Amgen Company Details
10.13.2 Amgen Business Overview and Its Total Revenue
10.13.3 Amgen Bio Similars/Subsequent Entry Biologic Introduction
10.13.4 Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.13.5 Amgen Recent Development
13.14 Samsung Biologics
10.14.1 Samsung Biologics Company Details
10.14.2 Samsung Biologics Business Overview and Its Total Revenue
10.14.3 Samsung Biologics Bio Similars/Subsequent Entry Biologic Introduction
10.14.4 Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.14.5 Samsung Biologics Recent Development
13.15 Mylan
10.15.1 Mylan Company Details
10.15.2 Mylan Business Overview and Its Total Revenue
10.15.3 Mylan Bio Similars/Subsequent Entry Biologic Introduction
10.15.4 Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.15.5 Mylan Recent Development
13.16 Dr. Reddy's Laboratories
10.16.1 Dr. Reddy's Laboratories Company Details
10.16.2 Dr. Reddy's Laboratories Business Overview and Its Total Revenue
10.16.3 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Introduction
10.16.4 Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.16.5 Dr. Reddy's Laboratories Recent Development
13.17 Stada Arzneimittel AG
10.17.1 Stada Arzneimittel AG Company Details
10.17.2 Stada Arzneimittel AG Business Overview and Its Total Revenue
10.17.3 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Introduction
10.17.4 Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.17.5 Stada Arzneimittel AG Recent Development
13.18 AbbVie
10.18.1 AbbVie Company Details
10.18.2 AbbVie Business Overview and Its Total Revenue
10.18.3 AbbVie Bio Similars/Subsequent Entry Biologic Introduction
10.18.4 AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.18.5 AbbVie Recent Development
13.19 Sanofi-Aventis
10.19.1 Sanofi-Aventis Company Details
10.19.2 Sanofi-Aventis Business Overview and Its Total Revenue
10.19.3 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Introduction
10.19.4 Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.19.5 Sanofi-Aventis Recent Development
13.20 Johnson & Johnson
10.20.1 Johnson & Johnson Company Details
10.20.2 Johnson & Johnson Business Overview and Its Total Revenue
10.20.3 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Introduction
10.20.4 Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.20.5 Johnson & Johnson Recent Development
13.21 Novo Nordisk
10.21.1 Novo Nordisk Company Details
10.21.2 Novo Nordisk Business Overview and Its Total Revenue
10.21.3 Novo Nordisk Bio Similars/Subsequent Entry Biologic Introduction
10.21.4 Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.21.5 Novo Nordisk Recent Development
13.22 Eli Lilly
10.22.1 Eli Lilly Company Details
10.22.2 Eli Lilly Business Overview and Its Total Revenue
10.22.3 Eli Lilly Bio Similars/Subsequent Entry Biologic Introduction
10.22.4 Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.22.5 Eli Lilly Recent Development
13.23 Novartis
10.23.1 Novartis Company Details
10.23.2 Novartis Business Overview and Its Total Revenue
10.23.3 Novartis Bio Similars/Subsequent Entry Biologic Introduction
10.23.4 Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.23.5 Novartis Recent Development
13.24 3sbio
10.24.1 3sbio Company Details
10.24.2 3sbio Business Overview and Its Total Revenue
10.24.3 3sbio Bio Similars/Subsequent Entry Biologic Introduction
10.24.4 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.24.5 3sbio Recent Development
13.25 Biotech
10.25.1 Biotech Company Details
10.25.2 Biotech Business Overview and Its Total Revenue
10.25.3 Biotech Bio Similars/Subsequent Entry Biologic Introduction
10.25.4 Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.25.5 Biotech Recent Development
13.26 Gelgen
10.26.1 Gelgen Company Details
10.26.2 Gelgen Business Overview and Its Total Revenue
10.26.3 Gelgen Bio Similars/Subsequent Entry Biologic Introduction
10.26.4 Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.26.5 Gelgen Recent Development
13.27 Innovent
10.27.1 Innovent Company Details
10.27.2 Innovent Business Overview and Its Total Revenue
10.27.3 Innovent Bio Similars/Subsequent Entry Biologic Introduction
10.27.4 Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.27.5 Innovent Recent Development
13.28 Dong Bao
10.28.1 Dong Bao Company Details
10.28.2 Dong Bao Business Overview and Its Total Revenue
10.28.3 Dong Bao Bio Similars/Subsequent Entry Biologic Introduction
10.28.4 Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.28.5 Dong Bao Recent Development
13.29 Ganlee
10.29.1 Ganlee Company Details
10.29.2 Ganlee Business Overview and Its Total Revenue
10.29.3 Ganlee Bio Similars/Subsequent Entry Biologic Introduction
10.29.4 Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.29.5 Ganlee Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Bio Similars/Subsequent Entry Biologic Revenue
1.4 Market Analysis by Type
1.4.1 Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Monoclonal Antibodies
1.4.3 Interferon
1.4.4 Erythropoietin
1.4.5 Insulin
1.4.6 Vaccines
1.4.7 Other
1.5 Market by Application
1.5.1 Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2020 VS 2026
1.5.2 Tumor
1.5.3 Diabetes
1.5.4 Cardiovascular
1.5.5 Hemophilia
1.5.6 Other
1.6 Coronavirus Disease 2019 (Covid-19): Bio Similars/Subsequent Entry Biologic Industry Impact
1.6.1 How the Covid-19 is Affecting the Bio Similars/Subsequent Entry Biologic Industry
1.6.1.1 Bio Similars/Subsequent Entry Biologic Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Bio Similars/Subsequent Entry Biologic Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Bio Similars/Subsequent Entry Biologic Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Bio Similars/Subsequent Entry Biologic Market Perspective (2015-2026)
2.2 Bio Similars/Subsequent Entry Biologic Growth Trends by Regions
2.2.1 Bio Similars/Subsequent Entry Biologic Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Bio Similars/Subsequent Entry Biologic Historic Market Share by Regions (2015-2020)
2.2.3 Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Bio Similars/Subsequent Entry Biologic Market Growth Strategy
2.3.6 Primary Interviews with Key Bio Similars/Subsequent Entry Biologic Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Market Size
3.1.1 Global Top Bio Similars/Subsequent Entry Biologic Players by Revenue (2015-2020)
3.1.2 Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Players (2015-2020)
3.1.3 Global Bio Similars/Subsequent Entry Biologic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio
3.2.1 Global Bio Similars/Subsequent Entry Biologic Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Bio Similars/Subsequent Entry Biologic Revenue in 2019
3.3 Bio Similars/Subsequent Entry Biologic Key Players Head office and Area Served
3.4 Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service
3.5 Date of Enter into Bio Similars/Subsequent Entry Biologic Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Bio Similars/Subsequent Entry Biologic Historic Market Size by Type (2015-2020)
4.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Type (2021-2026)
5 BIO SIMILARS/SUBSEQUENT ENTRY BIOLOGIC BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
5.2 Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
6.2 Bio Similars/Subsequent Entry Biologic Key Players in North America (2019-2020)
6.3 North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
6.4 North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
7.2 Bio Similars/Subsequent Entry Biologic Key Players in Europe (2019-2020)
7.3 Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
7.4 Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
8 CHINA
8.1 China Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
8.2 Bio Similars/Subsequent Entry Biologic Key Players in China (2019-2020)
8.3 China Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
8.4 China Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
9.2 Bio Similars/Subsequent Entry Biologic Key Players in Japan (2019-2020)
9.3 Japan Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
9.4 Japan Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
10.2 Bio Similars/Subsequent Entry Biologic Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
10.4 Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
11 INDIA
11.1 India Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
11.2 Bio Similars/Subsequent Entry Biologic Key Players in India (2019-2020)
11.3 India Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
11.4 India Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Bio Similars/Subsequent Entry Biologic Market Size (2015-2020)
12.2 Bio Similars/Subsequent Entry Biologic Key Players in Central & South America (2019-2020)
12.3 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020)
12.4 Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Sun Pharma
13.1.1 Sun Pharma Company Details
13.1.2 Sun Pharma Business Overview and Its Total Revenue
13.1.3 Sun Pharma Bio Similars/Subsequent Entry Biologic Introduction
13.1.4 Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020))
13.1.5 Sun Pharma Recent Development
13.2 Synthon Pharmaceuticals
13.2.1 Synthon Pharmaceuticals Company Details
13.2.2 Synthon Pharmaceuticals Business Overview and Its Total Revenue
13.2.3 Synthon Pharmaceuticals Bio Similars/Subsequent Entry Biologic Introduction
13.2.4 Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.2.5 Synthon Pharmaceuticals Recent Development
13.3 Teva Pharmaceutical Industries
13.3.1 Teva Pharmaceutical Industries Company Details
13.3.2 Teva Pharmaceutical Industries Business Overview and Its Total Revenue
13.3.3 Teva Pharmaceutical Industries Bio Similars/Subsequent Entry Biologic Introduction
13.3.4 Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.3.5 Teva Pharmaceutical Industries Recent Development
13.4 LG Life Sciences
13.4.1 LG Life Sciences Company Details
13.4.2 LG Life Sciences Business Overview and Its Total Revenue
13.4.3 LG Life Sciences Bio Similars/Subsequent Entry Biologic Introduction
13.4.4 LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.4.5 LG Life Sciences Recent Development
13.5 Celltrion Biocon
13.5.1 Celltrion Biocon Company Details
13.5.2 Celltrion Biocon Business Overview and Its Total Revenue
13.5.3 Celltrion Biocon Bio Similars/Subsequent Entry Biologic Introduction
13.5.4 Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.5.5 Celltrion Biocon Recent Development
13.6 Hospira
13.6.1 Hospira Company Details
13.6.2 Hospira Business Overview and Its Total Revenue
13.6.3 Hospira Bio Similars/Subsequent Entry Biologic Introduction
13.6.4 Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.6.5 Hospira Recent Development
13.7 Merck
13.7.1 Merck Company Details
13.7.2 Merck Business Overview and Its Total Revenue
13.7.3 Merck Bio Similars/Subsequent Entry Biologic Introduction
13.7.4 Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.7.5 Merck Recent Development
13.8 Biogen idec
13.8.1 Biogen idec Company Details
13.8.2 Biogen idec Business Overview and Its Total Revenue
13.8.3 Biogen idec Bio Similars/Subsequent Entry Biologic Introduction
13.8.4 Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.8.5 Biogen idec Recent Development
13.9 Genentech (Roche)
13.9.1 Genentech (Roche) Company Details
13.9.2 Genentech (Roche) Business Overview and Its Total Revenue
13.9.3 Genentech (Roche) Bio Similars/Subsequent Entry Biologic Introduction
13.9.4 Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.9.5 Genentech (Roche) Recent Development
13.10 Pfizer
13.10.1 Pfizer Company Details
13.10.2 Pfizer Business Overview and Its Total Revenue
13.10.3 Pfizer Bio Similars/Subsequent Entry Biologic Introduction
13.10.4 Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
13.10.5 Pfizer Recent Development
13.11 Celltrion
10.11.1 Celltrion Company Details
10.11.2 Celltrion Business Overview and Its Total Revenue
10.11.3 Celltrion Bio Similars/Subsequent Entry Biologic Introduction
10.11.4 Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.11.5 Celltrion Recent Development
13.12 Biocon
10.12.1 Biocon Company Details
10.12.2 Biocon Business Overview and Its Total Revenue
10.12.3 Biocon Bio Similars/Subsequent Entry Biologic Introduction
10.12.4 Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.12.5 Biocon Recent Development
13.13 Amgen
10.13.1 Amgen Company Details
10.13.2 Amgen Business Overview and Its Total Revenue
10.13.3 Amgen Bio Similars/Subsequent Entry Biologic Introduction
10.13.4 Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.13.5 Amgen Recent Development
13.14 Samsung Biologics
10.14.1 Samsung Biologics Company Details
10.14.2 Samsung Biologics Business Overview and Its Total Revenue
10.14.3 Samsung Biologics Bio Similars/Subsequent Entry Biologic Introduction
10.14.4 Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.14.5 Samsung Biologics Recent Development
13.15 Mylan
10.15.1 Mylan Company Details
10.15.2 Mylan Business Overview and Its Total Revenue
10.15.3 Mylan Bio Similars/Subsequent Entry Biologic Introduction
10.15.4 Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.15.5 Mylan Recent Development
13.16 Dr. Reddy's Laboratories
10.16.1 Dr. Reddy's Laboratories Company Details
10.16.2 Dr. Reddy's Laboratories Business Overview and Its Total Revenue
10.16.3 Dr. Reddy's Laboratories Bio Similars/Subsequent Entry Biologic Introduction
10.16.4 Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.16.5 Dr. Reddy's Laboratories Recent Development
13.17 Stada Arzneimittel AG
10.17.1 Stada Arzneimittel AG Company Details
10.17.2 Stada Arzneimittel AG Business Overview and Its Total Revenue
10.17.3 Stada Arzneimittel AG Bio Similars/Subsequent Entry Biologic Introduction
10.17.4 Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.17.5 Stada Arzneimittel AG Recent Development
13.18 AbbVie
10.18.1 AbbVie Company Details
10.18.2 AbbVie Business Overview and Its Total Revenue
10.18.3 AbbVie Bio Similars/Subsequent Entry Biologic Introduction
10.18.4 AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.18.5 AbbVie Recent Development
13.19 Sanofi-Aventis
10.19.1 Sanofi-Aventis Company Details
10.19.2 Sanofi-Aventis Business Overview and Its Total Revenue
10.19.3 Sanofi-Aventis Bio Similars/Subsequent Entry Biologic Introduction
10.19.4 Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.19.5 Sanofi-Aventis Recent Development
13.20 Johnson & Johnson
10.20.1 Johnson & Johnson Company Details
10.20.2 Johnson & Johnson Business Overview and Its Total Revenue
10.20.3 Johnson & Johnson Bio Similars/Subsequent Entry Biologic Introduction
10.20.4 Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.20.5 Johnson & Johnson Recent Development
13.21 Novo Nordisk
10.21.1 Novo Nordisk Company Details
10.21.2 Novo Nordisk Business Overview and Its Total Revenue
10.21.3 Novo Nordisk Bio Similars/Subsequent Entry Biologic Introduction
10.21.4 Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.21.5 Novo Nordisk Recent Development
13.22 Eli Lilly
10.22.1 Eli Lilly Company Details
10.22.2 Eli Lilly Business Overview and Its Total Revenue
10.22.3 Eli Lilly Bio Similars/Subsequent Entry Biologic Introduction
10.22.4 Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.22.5 Eli Lilly Recent Development
13.23 Novartis
10.23.1 Novartis Company Details
10.23.2 Novartis Business Overview and Its Total Revenue
10.23.3 Novartis Bio Similars/Subsequent Entry Biologic Introduction
10.23.4 Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.23.5 Novartis Recent Development
13.24 3sbio
10.24.1 3sbio Company Details
10.24.2 3sbio Business Overview and Its Total Revenue
10.24.3 3sbio Bio Similars/Subsequent Entry Biologic Introduction
10.24.4 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.24.5 3sbio Recent Development
13.25 Biotech
10.25.1 Biotech Company Details
10.25.2 Biotech Business Overview and Its Total Revenue
10.25.3 Biotech Bio Similars/Subsequent Entry Biologic Introduction
10.25.4 Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.25.5 Biotech Recent Development
13.26 Gelgen
10.26.1 Gelgen Company Details
10.26.2 Gelgen Business Overview and Its Total Revenue
10.26.3 Gelgen Bio Similars/Subsequent Entry Biologic Introduction
10.26.4 Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.26.5 Gelgen Recent Development
13.27 Innovent
10.27.1 Innovent Company Details
10.27.2 Innovent Business Overview and Its Total Revenue
10.27.3 Innovent Bio Similars/Subsequent Entry Biologic Introduction
10.27.4 Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.27.5 Innovent Recent Development
13.28 Dong Bao
10.28.1 Dong Bao Company Details
10.28.2 Dong Bao Business Overview and Its Total Revenue
10.28.3 Dong Bao Bio Similars/Subsequent Entry Biologic Introduction
10.28.4 Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.28.5 Dong Bao Recent Development
13.29 Ganlee
10.29.1 Ganlee Company Details
10.29.2 Ganlee Business Overview and Its Total Revenue
10.29.3 Ganlee Bio Similars/Subsequent Entry Biologic Introduction
10.29.4 Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
10.29.5 Ganlee Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Bio Similars/Subsequent Entry Biologic Key Market Segments
Table 2. Key Players Covered: Ranking by Bio Similars/Subsequent Entry Biologic Revenue
Table 3. Ranking of Global Top Bio Similars/Subsequent Entry Biologic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Monoclonal Antibodies
Table 6. Key Players of Interferon
Table 7. Key Players of Erythropoietin
Table 8. Key Players of Insulin
Table 9. Key Players of Vaccines
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four Bio Similars/Subsequent Entry Biologic Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Bio Similars/Subsequent Entry Biologic Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Bio Similars/Subsequent Entry Biologic Players to Combat Covid-19 Impact
Table 16. Global Bio Similars/Subsequent Entry Biologic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2015-2020)
Table 20. Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Bio Similars/Subsequent Entry Biologic Market Growth Strategy
Table 26. Main Points Interviewed from Key Bio Similars/Subsequent Entry Biologic Players
Table 27. Global Bio Similars/Subsequent Entry Biologic Revenue by Players (2015-2020) (Million US$)
Table 28. Global Bio Similars/Subsequent Entry Biologic Market Share by Players (2015-2020)
Table 29. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2019)
Table 30. Global Bio Similars/Subsequent Entry Biologic by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service
Table 33. Date of Enter into Bio Similars/Subsequent Entry Biologic Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 36. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Type (2015-2020)
Table 37. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2021-2026)
Table 38. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Application (2015-2020)
Table 39. Global Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 40. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Application (2021-2026)
Table 41. North America Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 43. North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 44. North America Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 45. North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 46. North America Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 47. Europe Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 49. Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 51. Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 53. China Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 54. China Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 55. China Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 56. China Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 57. China Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 58. China Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 59. Japan Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 61. Japan Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 63. Japan Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 67. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 69. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 71. India Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 72. India Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 73. India Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 74. India Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 75. India Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 76. India Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 79. Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 81. Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 83. Sun Pharma Company Details
Table 84. Sun Pharma Business Overview
Table 85. Sun Pharma Product
Table 86. Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 87. Sun Pharma Recent Development
Table 88. Synthon Pharmaceuticals Company Details
Table 89. Synthon Pharmaceuticals Business Overview
Table 90. Synthon Pharmaceuticals Product
Table 91. Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 92. Synthon Pharmaceuticals Recent Development
Table 93. Teva Pharmaceutical Industries Company Details
Table 94. Teva Pharmaceutical Industries Business Overview
Table 95. Teva Pharmaceutical Industries Product
Table 96. Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 97. Teva Pharmaceutical Industries Recent Development
Table 98. LG Life Sciences Company Details
Table 99. LG Life Sciences Business Overview
Table 100. LG Life Sciences Product
Table 101. LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 102. LG Life Sciences Recent Development
Table 103. Celltrion Biocon Company Details
Table 104. Celltrion Biocon Business Overview
Table 105. Celltrion Biocon Product
Table 106. Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 107. Celltrion Biocon Recent Development
Table 108. Hospira Company Details
Table 109. Hospira Business Overview
Table 110. Hospira Product
Table 111. Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 112. Hospira Recent Development
Table 113. Merck Company Details
Table 114. Merck Business Overview
Table 115. Merck Product
Table 116. Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 117. Merck Recent Development
Table 118. Biogen idec Business Overview
Table 119. Biogen idec Product
Table 120. Biogen idec Company Details
Table 121. Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 122. Biogen idec Recent Development
Table 123. Genentech (Roche) Company Details
Table 124. Genentech (Roche) Business Overview
Table 125. Genentech (Roche) Product
Table 126. Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 127. Genentech (Roche) Recent Development
Table 128. Pfizer Company Details
Table 129. Pfizer Business Overview
Table 130. Pfizer Product
Table 131. Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 132. Pfizer Recent Development
Table 133. Celltrion Company Details
Table 134. Celltrion Business Overview
Table 135. Celltrion Product
Table 136. Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 137. Celltrion Recent Development
Table 138. Biocon Company Details
Table 139. Biocon Business Overview
Table 140. Biocon Product
Table 141. Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 142. Biocon Recent Development
Table 143. Amgen Company Details
Table 144. Amgen Business Overview
Table 145. Amgen Product
Table 146. Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 147. Amgen Recent Development
Table 148. Samsung Biologics Company Details
Table 149. Samsung Biologics Business Overview
Table 150. Samsung Biologics Product
Table 151. Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 152. Samsung Biologics Recent Development
Table 153. Mylan Company Details
Table 154. Mylan Business Overview
Table 155. Mylan Product
Table 156. Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 157. Mylan Recent Development
Table 158. Dr. Reddy's Laboratories Company Details
Table 159. Dr. Reddy's Laboratories Business Overview
Table 160. Dr. Reddy's Laboratories Product
Table 161. Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 162. Dr. Reddy's Laboratories Recent Development
Table 163. Stada Arzneimittel AG Company Details
Table 164. Stada Arzneimittel AG Business Overview
Table 165. Stada Arzneimittel AG Product
Table 166. Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 167. Stada Arzneimittel AG Recent Development
Table 168. AbbVie Company Details
Table 169. AbbVie Business Overview
Table 170. AbbVie Product
Table 171. AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 172. AbbVie Recent Development
Table 173. Sanofi-Aventis Company Details
Table 174. Sanofi-Aventis Business Overview
Table 175. Sanofi-Aventis Product
Table 176. Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 177. Sanofi-Aventis Recent Development
Table 178. Johnson & Johnson Company Details
Table 179. Johnson & Johnson Business Overview
Table 180. Johnson & Johnson Product
Table 181. Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 182. Johnson & Johnson Recent Development
Table 183. Novo Nordisk Company Details
Table 184. Novo Nordisk Business Overview
Table 185. Novo Nordisk Product
Table 186. Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 187. Novo Nordisk Recent Development
Table 188. Eli Lilly Company Details
Table 189. Eli Lilly Business Overview
Table 190. Eli Lilly Product
Table 191. Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 192. Eli Lilly Recent Development
Table 193. Novartis Company Details
Table 194. Novartis Business Overview
Table 195. Novartis Product
Table 196. Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 197. Novartis Recent Development
Table 198. 3sbio Company Details
Table 199. 3sbio Business Overview
Table 200. 3sbio Product
Table 201. 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 202. 3sbio Recent Development
Table 203. Biotech Company Details
Table 204. Biotech Business Overview
Table 205. Biotech Product
Table 206. Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 207. Biotech Recent Development
Table 208. Gelgen Company Details
Table 209. Gelgen Business Overview
Table 210. Gelgen Product
Table 211. Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 212. Gelgen Recent Development
Table 213. Innovent Company Details
Table 214. Innovent Business Overview
Table 215. Innovent Product
Table 216. Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 217. Innovent Recent Development
Table 218. Dong Bao Company Details
Table 219. Dong Bao Business Overview
Table 220. Dong Bao Product
Table 221. Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 222. Dong Bao Recent Development
Table 223. Ganlee Company Details
Table 224. Ganlee Business Overview
Table 225. Ganlee Product
Table 226. Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 227. Ganlee Recent Development
Table 228. Research Programs/Design for This Report
Table 229. Key Data Information from Secondary Sources
Table 230. Key Data Information from Primary Sources
Table 1. Bio Similars/Subsequent Entry Biologic Key Market Segments
Table 2. Key Players Covered: Ranking by Bio Similars/Subsequent Entry Biologic Revenue
Table 3. Ranking of Global Top Bio Similars/Subsequent Entry Biologic Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Bio Similars/Subsequent Entry Biologic Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Monoclonal Antibodies
Table 6. Key Players of Interferon
Table 7. Key Players of Erythropoietin
Table 8. Key Players of Insulin
Table 9. Key Players of Vaccines
Table 10. Key Players of Other
Table 11. COVID-19 Impact Global Market: (Four Bio Similars/Subsequent Entry Biologic Market Size Forecast Scenarios)
Table 12. Opportunities and Trends for Bio Similars/Subsequent Entry Biologic Players in the COVID-19 Landscape
Table 13. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 14. Key Regions/Countries Measures against Covid-19 Impact
Table 15. Proposal for Bio Similars/Subsequent Entry Biologic Players to Combat Covid-19 Impact
Table 16. Global Bio Similars/Subsequent Entry Biologic Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 17. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (US$ Million): 2020 VS 2026
Table 18. Global Bio Similars/Subsequent Entry Biologic Market Size by Regions (2015-2020) (US$ Million)
Table 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2015-2020)
Table 20. Global Bio Similars/Subsequent Entry Biologic Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 21. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2021-2026)
Table 22. Market Top Trends
Table 23. Key Drivers: Impact Analysis
Table 24. Key Challenges
Table 25. Bio Similars/Subsequent Entry Biologic Market Growth Strategy
Table 26. Main Points Interviewed from Key Bio Similars/Subsequent Entry Biologic Players
Table 27. Global Bio Similars/Subsequent Entry Biologic Revenue by Players (2015-2020) (Million US$)
Table 28. Global Bio Similars/Subsequent Entry Biologic Market Share by Players (2015-2020)
Table 29. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2019)
Table 30. Global Bio Similars/Subsequent Entry Biologic by Players Market Concentration Ratio (CR5 and HHI)
Table 31. Key Players Headquarters and Area Served
Table 32. Key Players Bio Similars/Subsequent Entry Biologic Product Solution and Service
Table 33. Date of Enter into Bio Similars/Subsequent Entry Biologic Market
Table 34. Mergers & Acquisitions, Expansion Plans
Table 35. Global Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 36. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Type (2015-2020)
Table 37. Global Bio Similars/Subsequent Entry Biologic Revenue Market Share by Type (2021-2026)
Table 38. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Application (2015-2020)
Table 39. Global Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 40. Global Bio Similars/Subsequent Entry Biologic Market Size Share by Application (2021-2026)
Table 41. North America Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 42. North America Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 43. North America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 44. North America Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 45. North America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 46. North America Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 47. Europe Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 48. Europe Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 49. Europe Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 50. Europe Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 51. Europe Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 52. Europe Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 53. China Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 54. China Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 55. China Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 56. China Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 57. China Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 58. China Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 59. Japan Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 60. Japan Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 61. Japan Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 62. Japan Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 63. Japan Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 64. Japan Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 65. Southeast Asia Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 66. Southeast Asia Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 67. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 68. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 69. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 70. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 71. India Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 72. India Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 73. India Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 74. India Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 75. India Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 76. India Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 77. Central & South America Key Players Bio Similars/Subsequent Entry Biologic Revenue (2019-2020) (Million US$)
Table 78. Central & South America Key Players Bio Similars/Subsequent Entry Biologic Market Share (2019-2020)
Table 79. Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Type (2015-2020) (Million US$)
Table 80. Central & South America Bio Similars/Subsequent Entry Biologic Market Share by Type (2015-2020)
Table 81. Central & South America Bio Similars/Subsequent Entry Biologic Market Size by Application (2015-2020) (Million US$)
Table 82. Central & South America Bio Similars/Subsequent Entry Biologic Market Share by Application (2015-2020)
Table 83. Sun Pharma Company Details
Table 84. Sun Pharma Business Overview
Table 85. Sun Pharma Product
Table 86. Sun Pharma Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 87. Sun Pharma Recent Development
Table 88. Synthon Pharmaceuticals Company Details
Table 89. Synthon Pharmaceuticals Business Overview
Table 90. Synthon Pharmaceuticals Product
Table 91. Synthon Pharmaceuticals Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 92. Synthon Pharmaceuticals Recent Development
Table 93. Teva Pharmaceutical Industries Company Details
Table 94. Teva Pharmaceutical Industries Business Overview
Table 95. Teva Pharmaceutical Industries Product
Table 96. Teva Pharmaceutical Industries Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 97. Teva Pharmaceutical Industries Recent Development
Table 98. LG Life Sciences Company Details
Table 99. LG Life Sciences Business Overview
Table 100. LG Life Sciences Product
Table 101. LG Life Sciences Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 102. LG Life Sciences Recent Development
Table 103. Celltrion Biocon Company Details
Table 104. Celltrion Biocon Business Overview
Table 105. Celltrion Biocon Product
Table 106. Celltrion Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 107. Celltrion Biocon Recent Development
Table 108. Hospira Company Details
Table 109. Hospira Business Overview
Table 110. Hospira Product
Table 111. Hospira Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 112. Hospira Recent Development
Table 113. Merck Company Details
Table 114. Merck Business Overview
Table 115. Merck Product
Table 116. Merck Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 117. Merck Recent Development
Table 118. Biogen idec Business Overview
Table 119. Biogen idec Product
Table 120. Biogen idec Company Details
Table 121. Biogen idec Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 122. Biogen idec Recent Development
Table 123. Genentech (Roche) Company Details
Table 124. Genentech (Roche) Business Overview
Table 125. Genentech (Roche) Product
Table 126. Genentech (Roche) Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 127. Genentech (Roche) Recent Development
Table 128. Pfizer Company Details
Table 129. Pfizer Business Overview
Table 130. Pfizer Product
Table 131. Pfizer Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 132. Pfizer Recent Development
Table 133. Celltrion Company Details
Table 134. Celltrion Business Overview
Table 135. Celltrion Product
Table 136. Celltrion Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 137. Celltrion Recent Development
Table 138. Biocon Company Details
Table 139. Biocon Business Overview
Table 140. Biocon Product
Table 141. Biocon Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 142. Biocon Recent Development
Table 143. Amgen Company Details
Table 144. Amgen Business Overview
Table 145. Amgen Product
Table 146. Amgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 147. Amgen Recent Development
Table 148. Samsung Biologics Company Details
Table 149. Samsung Biologics Business Overview
Table 150. Samsung Biologics Product
Table 151. Samsung Biologics Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 152. Samsung Biologics Recent Development
Table 153. Mylan Company Details
Table 154. Mylan Business Overview
Table 155. Mylan Product
Table 156. Mylan Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 157. Mylan Recent Development
Table 158. Dr. Reddy's Laboratories Company Details
Table 159. Dr. Reddy's Laboratories Business Overview
Table 160. Dr. Reddy's Laboratories Product
Table 161. Dr. Reddy's Laboratories Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 162. Dr. Reddy's Laboratories Recent Development
Table 163. Stada Arzneimittel AG Company Details
Table 164. Stada Arzneimittel AG Business Overview
Table 165. Stada Arzneimittel AG Product
Table 166. Stada Arzneimittel AG Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 167. Stada Arzneimittel AG Recent Development
Table 168. AbbVie Company Details
Table 169. AbbVie Business Overview
Table 170. AbbVie Product
Table 171. AbbVie Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 172. AbbVie Recent Development
Table 173. Sanofi-Aventis Company Details
Table 174. Sanofi-Aventis Business Overview
Table 175. Sanofi-Aventis Product
Table 176. Sanofi-Aventis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 177. Sanofi-Aventis Recent Development
Table 178. Johnson & Johnson Company Details
Table 179. Johnson & Johnson Business Overview
Table 180. Johnson & Johnson Product
Table 181. Johnson & Johnson Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 182. Johnson & Johnson Recent Development
Table 183. Novo Nordisk Company Details
Table 184. Novo Nordisk Business Overview
Table 185. Novo Nordisk Product
Table 186. Novo Nordisk Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 187. Novo Nordisk Recent Development
Table 188. Eli Lilly Company Details
Table 189. Eli Lilly Business Overview
Table 190. Eli Lilly Product
Table 191. Eli Lilly Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 192. Eli Lilly Recent Development
Table 193. Novartis Company Details
Table 194. Novartis Business Overview
Table 195. Novartis Product
Table 196. Novartis Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 197. Novartis Recent Development
Table 198. 3sbio Company Details
Table 199. 3sbio Business Overview
Table 200. 3sbio Product
Table 201. 3sbio Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 202. 3sbio Recent Development
Table 203. Biotech Company Details
Table 204. Biotech Business Overview
Table 205. Biotech Product
Table 206. Biotech Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 207. Biotech Recent Development
Table 208. Gelgen Company Details
Table 209. Gelgen Business Overview
Table 210. Gelgen Product
Table 211. Gelgen Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 212. Gelgen Recent Development
Table 213. Innovent Company Details
Table 214. Innovent Business Overview
Table 215. Innovent Product
Table 216. Innovent Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 217. Innovent Recent Development
Table 218. Dong Bao Company Details
Table 219. Dong Bao Business Overview
Table 220. Dong Bao Product
Table 221. Dong Bao Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 222. Dong Bao Recent Development
Table 223. Ganlee Company Details
Table 224. Ganlee Business Overview
Table 225. Ganlee Product
Table 226. Ganlee Revenue in Bio Similars/Subsequent Entry Biologic Business (2015-2020) (Million US$)
Table 227. Ganlee Recent Development
Table 228. Research Programs/Design for This Report
Table 229. Key Data Information from Secondary Sources
Table 230. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Bio Similars/Subsequent Entry Biologic Market Share by Type: 2020 VS 2026
Figure 2. Monoclonal Antibodies Features
Figure 3. Interferon Features
Figure 4. Erythropoietin Features
Figure 5. Insulin Features
Figure 6. Vaccines Features
Figure 7. Other Features
Figure 8. Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2020 VS 2026
Figure 9. Tumor Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Cardiovascular Case Studies
Figure 12. Hemophilia Case Studies
Figure 13. Other Case Studies
Figure 14. Bio Similars/Subsequent Entry Biologic Report Years Considered
Figure 15. Global Bio Similars/Subsequent Entry Biologic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions: 2020 VS 2026
Figure 17. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Players in 2019
Figure 20. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Bio Similars/Subsequent Entry Biologic Revenue in 2019
Figure 22. North America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Sun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Sun Pharma Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 31. Synthon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Synthon Pharmaceuticals Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 33. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Teva Pharmaceutical Industries Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 35. LG Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. LG Life Sciences Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 37. Celltrion Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Celltrion Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 39. Hospira Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Hospira Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 41. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Merck Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 43. Biogen idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Biogen idec Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 45. Genentech (Roche) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Genentech (Roche) Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 47. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Pfizer Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 49. Celltrion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Celltrion Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 51. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 53. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Amgen Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 55. Samsung Biologics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Samsung Biologics Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 57. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Mylan Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 59. Dr. Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Dr. Reddy's Laboratories Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 61. Stada Arzneimittel AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Stada Arzneimittel AG Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 63. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. AbbVie Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 65. Sanofi-Aventis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Sanofi-Aventis Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 67. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Johnson & Johnson Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Global Bio Similars/Subsequent Entry Biologic Market Share by Type: 2020 VS 2026
Figure 2. Monoclonal Antibodies Features
Figure 3. Interferon Features
Figure 4. Erythropoietin Features
Figure 5. Insulin Features
Figure 6. Vaccines Features
Figure 7. Other Features
Figure 8. Global Bio Similars/Subsequent Entry Biologic Market Share by Application: 2020 VS 2026
Figure 9. Tumor Case Studies
Figure 10. Diabetes Case Studies
Figure 11. Cardiovascular Case Studies
Figure 12. Hemophilia Case Studies
Figure 13. Other Case Studies
Figure 14. Bio Similars/Subsequent Entry Biologic Report Years Considered
Figure 15. Global Bio Similars/Subsequent Entry Biologic Market Size YoY Growth 2015-2026 (US$ Million)
Figure 16. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions: 2020 VS 2026
Figure 17. Global Bio Similars/Subsequent Entry Biologic Market Share by Regions (2021-2026)
Figure 18. Porter's Five Forces Analysis
Figure 19. Global Bio Similars/Subsequent Entry Biologic Market Share by Players in 2019
Figure 20. Global Top Bio Similars/Subsequent Entry Biologic Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bio Similars/Subsequent Entry Biologic as of 2019
Figure 21. The Top 10 and 5 Players Market Share by Bio Similars/Subsequent Entry Biologic Revenue in 2019
Figure 22. North America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Europe Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. China Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Japan Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 26. Southeast Asia Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 27. India Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 28. Central & South America Bio Similars/Subsequent Entry Biologic Market Size YoY Growth (2015-2020) (Million US$)
Figure 29. Sun Pharma Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Sun Pharma Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 31. Synthon Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Synthon Pharmaceuticals Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 33. Teva Pharmaceutical Industries Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Teva Pharmaceutical Industries Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 35. LG Life Sciences Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. LG Life Sciences Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 37. Celltrion Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Celltrion Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 39. Hospira Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Hospira Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 41. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Merck Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 43. Biogen idec Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Biogen idec Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 45. Genentech (Roche) Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. Genentech (Roche) Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 47. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Pfizer Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 49. Celltrion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Celltrion Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 51. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Biocon Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 53. Amgen Total Revenue (US$ Million): 2019 Compared with 2018
Figure 54. Amgen Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 55. Samsung Biologics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 56. Samsung Biologics Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 57. Mylan Total Revenue (US$ Million): 2019 Compared with 2018
Figure 58. Mylan Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 59. Dr. Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 60. Dr. Reddy's Laboratories Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 61. Stada Arzneimittel AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 62. Stada Arzneimittel AG Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 63. AbbVie Total Revenue (US$ Million): 2019 Compared with 2018
Figure 64. AbbVie Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 65. Sanofi-Aventis Total Revenue (US$ Million): 2019 Compared with 2018
Figure 66. Sanofi-Aventis Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 67. Johnson & Johnson Total Revenue (US$ Million): 2019 Compared with 2018
Figure 68. Johnson & Johnson Revenue Growth Rate in Bio Similars/Subsequent Entry Biologic Business (2015-2020)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
